Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.
2.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

3.

A case for the use of validated physiological mortality metrics to guide early family intervention in intensive care unit patients.

Searl MF.

AACN Adv Crit Care. 2015 Jan-Mar;26(1):13-22; quiz 23-4. doi: 10.1097/NCI.0000000000000063. Review.

PMID:
25594474
4.

Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial.

Agboola S, Flanagan C, Searl M, Elfiky A, Kvedar J, Jethwani K.

JMIR Res Protoc. 2014 Dec 23;3(4):e79. doi: 10.2196/resprot.4041.

5.

Pain management in cancer patients using a mobile app: study design of a randomized controlled trial.

Agboola S, Kamdar M, Flanagan C, Searl M, Traeger L, Kvedar J, Jethwani K.

JMIR Res Protoc. 2014 Dec 12;3(4):e76. doi: 10.2196/resprot.3957.

6.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

7.

You don't say: dynamic aphasia, another variant of primary progressive aphasia?

Perez DL, Dickerson BC, McGinnis SM, Sapolsky D, Johnson K, Searl M, Daffner KR.

J Alzheimers Dis. 2013;34(1):139-44. doi: 10.3233/JAD-121861.

8.

It is time to talk about people: a human-centered healthcare system.

Searl MM, Borgi L, Chemali Z.

Health Res Policy Syst. 2010 Nov 26;8:35. doi: 10.1186/1478-4505-8-35.

9.

The dysexecutive syndromes.

Daffner KR, Searl MM.

Handb Clin Neurol. 2008;88:249-67. doi: 10.1016/S0072-9752(07)88012-2. No abstract available.

PMID:
18631695
10.

IQ-based norms for highly intelligent adults.

Rentz DM, Sardinha LM, Huh TJ, Searl MM, Daffner KR, Sperling RA.

Clin Neuropsychol. 2006 Dec;20(4):637-48.

PMID:
16980251
11.

Sequence? What Sequence?: the human medial temporal lobe and sequence learning.

Schendan HE, Searl MM, Melrose RJ, Stern CE.

Mol Psychiatry. 2003 Nov;8(11):896-7. Review. No abstract available.

PMID:
14593424
12.

An FMRI study of the role of the medial temporal lobe in implicit and explicit sequence learning.

Schendan HE, Searl MM, Melrose RJ, Stern CE.

Neuron. 2003 Mar 27;37(6):1013-25.

13.

Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance.

Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, Saper CB, Rauch SL.

Biol Psychiatry. 2000 Jul 15;48(2):99-109.

PMID:
10903406
14.

Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI.

Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E, Saper CB, Warach S.

Biol Psychiatry. 1999 May 1;45(9):1128-37.

PMID:
10331104
15.

Energy sources: a realistic outlook.

Starr C, Searl MF, Alpert S.

Science. 1992 May 15;256(5059):981-7.

PMID:
17795000
16.

Uranium resources.

Searl MF, Platt J.

Science. 1977 May 6;196(4290):603-4. No abstract available.

PMID:
17760033

Supplemental Content

Loading ...
Support Center